Hissey Kientz Concerned That Patients Have Not Been Provided With Crucial Information About Digitek Recall Despite the Dangers of Digoxi...( Hissey Kient...),Health

Hissey Kientz, LLP is concerned that despite a recent recall notice for the heart drug Digitek, the drug’s manufacturer has failed to provide any additional information on how long the heart medication was being improperly manufactured. According to a press release issued by the manufacturer, some Digitek tablets may have been manufactured at double their normal strength, meaning that patients could receive a double dose of the drug, leading to an overdose. A Digitek overdose could lead to severe side effects, including heart attack, stroke or death.

Austin, TX (Vocus) August 16, 2008 -- The law firm of Hissey Kientz, LLP is concerned over recent reports that many heart patients may not have been fully informed by the drug’s manufacturer about problems with the heart drug Digitek. Drugmaker Actavis Totowa issued a nationwide recall notice for the heart drug http://www.hkllp.com/digitek/digitek.html [Digitek] (digoxin) on April 25, 2008.

In a press release announcing the recall notice, the company stated that some Digitek tablets may have been manufactured at twice their normal thickness, meaning that patients could receive a double-dose of the drug. This increased exposure could cause patients to suffer an overdose, leading to heart attack, stroke or death.

But according to a statement by the Food and Drug Administration published on May 1, 2008, since the Digitek recall was issued doctors and patients have received no additional information on how long the drug was being produced at twice the normal strength. The public has also not been notified on how many lots of the heart medication were improperly manufactured and when this problem was first detected.

“Actavis has a responsibility to provide consumers with all the available safety information about the manufacturing p
'/>"/>